LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Search

Xencor Inc

Ouvert

SecteurSoins de santé

12.73 -7.69

Résumé

Variation du prix de l'action

24h

Actuel

Min

12.68

Max

13.82

Chiffres clés

By Trading Economics

Revenu

25M

-6M

Ventes

-23M

21M

Marge bénéficiaire

-28.701

Employés

250

EBITDA

24M

4.2M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+113.14% upside

Dividendes

By Dow Jones

Prochains Résultats

5 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-168M

826M

Ouverture précédente

20.42

Clôture précédente

12.73

Sentiment de l'Actualité

By Acuity

50%

50%

168 / 352 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Xencor Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 févr. 2026, 22:04 UTC

Résultats

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

26 févr. 2026, 23:55 UTC

Market Talk

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

26 févr. 2026, 23:40 UTC

Acquisitions, Fusions, Rachats

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

26 févr. 2026, 23:37 UTC

Market Talk

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

26 févr. 2026, 23:32 UTC

Résultats

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

26 févr. 2026, 23:19 UTC

Acquisitions, Fusions, Rachats

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 févr. 2026, 23:18 UTC

Acquisitions, Fusions, Rachats

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 févr. 2026, 23:12 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Equities Roundup: Market Talk

26 févr. 2026, 23:12 UTC

Market Talk
Acquisitions, Fusions, Rachats

Netflix Gives Up in Bidding War Over Warner -- Market Talk

26 févr. 2026, 23:01 UTC

Acquisitions, Fusions, Rachats

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 févr. 2026, 23:00 UTC

Acquisitions, Fusions, Rachats

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 févr. 2026, 23:00 UTC

Acquisitions, Fusions, Rachats

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 févr. 2026, 22:55 UTC

Acquisitions, Fusions, Rachats

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 févr. 2026, 22:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26 févr. 2026, 22:43 UTC

Market Talk

RBA Hike In March Is Being Underpriced -- Market Talk

26 févr. 2026, 22:33 UTC

Acquisitions, Fusions, Rachats

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 févr. 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 févr. 2026, 22:13 UTC

Market Talk
Acquisitions, Fusions, Rachats

Bidding War Over Warner Bros. Set to Continue -- Market Talk

26 févr. 2026, 21:59 UTC

Résultats

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

26 févr. 2026, 21:58 UTC

Acquisitions, Fusions, Rachats

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 févr. 2026, 21:49 UTC

Résultats

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

26 févr. 2026, 21:45 UTC

Résultats

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

26 févr. 2026, 21:44 UTC

Résultats

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

26 févr. 2026, 21:44 UTC

Résultats

Coles Expects Market to Remain Highly Competitive

26 févr. 2026, 21:44 UTC

Résultats

Coles Says Supermarket Customers Remain Value Oriented

26 févr. 2026, 21:43 UTC

Résultats

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

26 févr. 2026, 21:43 UTC

Résultats

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

26 févr. 2026, 21:42 UTC

Acquisitions, Fusions, Rachats

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

26 févr. 2026, 21:41 UTC

Résultats
Acquisitions, Fusions, Rachats

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Comparaison

Variation de prix

Xencor Inc prévision

Objectif de Prix

By TipRanks

113.14% hausse

Prévisions sur 12 Mois

Moyen 28.88 USD  113.14%

Haut 43 USD

Bas 19 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

9

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

7.87 / 10.84Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

168 / 352Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.
help-icon Live chat